Pharmaceutical Price Transparency Should Be Policy Goal - Schondelmeyer
Policy making efforts should focus on pharmaceutical price transparency as a method to lower drug costs, PRIME Institute Director Stephen Schondelmeyer, PhD, told the HHS conference on drug pricing Aug. 8 in Washington, D.C.
You may also be interested in...
Deeply discounted launch prices for brand name pharmaceuticals are rare because promotional costs are high regardless of price, AstraZeneca Director of Public Policy Robert Freeman, PhD, suggested during the HHS conference on drug pricing Aug. 8 in Washington, D.C.
The Merck-Medco/Reader's Digest consumer discount plan offers enrollees an average discount of 18% for mail-service prescriptions, Merck-Medco said.
Average per capita spending on drugs for Medicare eligibles with drug insurance was 66% higher in 1996 than spending on pharmaceuticals for non-covered elderly, according to an analysis of drug spending released by the Clinton Administration on April 10.